Microdosing will see at least 5 new FDA-approved IND applications filed before December 2026.

Small, sub-perceptual doses of psychedelics (microdosing) are becoming the next big clinical research area because they don't require expensive therapist sessions — making them easier to prescribe and scale.

Microdosing identified as 'next clinical trial gold rush.' Scalability advantage over therapist-intensive models. EO fast-track provisions apply to all psychedelic INDs. Low IND filing barriers. 91% reflects strong market pull.